Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
aheadofprint:
30
12
2020
received:
03
07
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
28
5
2021
Statut:
epublish
Résumé
Not available.
Identifiants
pubmed: 33375771
doi: 10.3324/haematol.2020.265611
pmc: PMC8252923
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
2013-2017Références
Cell. 2011 Nov 23;147(5):1024-39
pubmed: 22118460
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
Science. 2014 Jan 17;343(6168):301-5
pubmed: 24292625
Blood. 2011 Nov 3;118(18):4771-9
pubmed: 21860026
Science. 2014 Jan 17;343(6168):305-9
pubmed: 24292623
Cancer Res. 2007 Sep 15;67(18):8839-46
pubmed: 17875725
Cell Rep. 2016 May 17;15(7):1554-1565
pubmed: 27160905
Elife. 2018 Jun 18;7:
pubmed: 29911972
Crit Rev Biochem Mol Biol. 2013 Nov-Dec;48(6):575-608
pubmed: 24088064
Cancer Cell. 2014 Jan 13;25(1):9-11
pubmed: 24434206
J Clin Pharmacol. 2011 May;51(5):731-8
pubmed: 20484616
PLoS One. 2017 Jan 3;12(1):e0169338
pubmed: 28046085
Annu Rev Biochem. 2013;82:139-70
pubmed: 23495937
Leukemia. 2019 Jan;33(1):171-180
pubmed: 30026574
Blood. 2018 Sep 20;132(12):1293-1303
pubmed: 30042095